Overview A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) Status: Completed Trial end date: 2008-10-01 Target enrollment: Participant gender: Summary The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with ADHD. Phase: Phase 2 Details Lead Sponsor: AbbVie (prior sponsor, Abbott)